![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
T Walle, UK Walle and LS Olanoff
A recent study, identifying several sulfate conjugates, appears to have led to a full qualitative account of propranolol metabolism in man. The objective of the present investigation was to determine the quantitative fate of propranolol, including the relationship between the primary metabolic pathways, i.e. glucuronidation, side-chain oxidation and ring oxidation. Single 80-mg oral doses of propranolol together with [3H]propranolol were administered to seven normal subjects. Urinary metabolites were determined by HPLC with radiometric detection after hydrolysis of glucuronic acid conjugates and fractionation by solvent extraction. About 90% of the dose was recovered in urine. Twelve metabolites accounted for 91% of the recovered dose. When examining the metabolites based on the primary metabolic pathways, 17% of the dose (range, 10-25%) was going through glucuronidation, 41% (range, 32-50%) through side-chain oxidation, and 42% (range, 27-59%) through ring oxidation. These data show that the net elimination of propranolol is largely due to oxidative metabolism. The relative contribution of the primary pathways is well reflected by the four major propranolol metabolites, i.e. propranolol glucuronide, naphthoxylactic acid, and the glucuronic acid and sulfate conjugates of 4'-hydroxypropranolol. These observations should greatly facilitate future studies of the biochemical mechanisms of propranolol disposition.
This article has been cited by other articles:
|
|
 |
|
  J. P. Gibbs, R. Hyland, and K. Youdim Minimizing Polymorphic Metabolism in Drug Discovery: Evaluation of the Utility of in Vitro Methods for Predicting Pharmacokinetic Consequences Associated with CYP2D6 Metabolism Drug Metab. Dispos., September 1, 2006; 34(9): 1516 - 1522. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Sten, S. Qvisen, P. Uutela, L. Luukkanen, R. Kostiainen, and M. Finel Prominent but Reverse Stereoselectivity in Propranolol Glucuronidation by Human UDP-Glucuronosyltransferases 1A9 and 1A10 Drug Metab. Dispos., September 1, 2006; 34(9): 1488 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. T. Mak and W. B. Weglicki Potent Antioxidant Properties of 4-Hydroxyl-propranolol J. Pharmacol. Exp. Ther., January 1, 2004; 308(1): 85 - 90. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Lu, M. L. Schrag, D. E. Slaughter, C. E. Raab, M. Shou, and A. D. Rodrigues MECHANISM-BASED INHIBITION OF HUMAN LIVER MICROSOMAL CYTOCHROME P450 1A2 BY ZILEUTON, A 5-LIPOXYGENASE INHIBITOR Drug Metab. Dispos., November 1, 2003; 31(11): 1352 - 1360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. L. Upthagrove and W. L. Nelson Importance of Amine pKa and Distribution Coefficient in the Metabolism of Fluorinated Propranolol Analogs: Metabolism by CYP1A2 Drug Metab. Dispos., November 1, 2001; 29(11): 1389 - 1395. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. A. Ring, H. Ghabrial, M. S. Ching, A. Shulkes, R. A. Smallwood, and D. J. Morgan Propranolol Elimination by Right and Left Fetal Liver: Studies in the Intact Isolated Perfused Fetal Sheep Liver J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 535 - 541. [Abstract] [Full Text]
|
|
|
|
|
|
R. S. Obach Nonspecific Binding to Microsomes: Impact on Scale-Up of in Vitro Intrinsic Clearance to Hepatic Clearance as Assessed Through Examination of Warfarin, Imipramine, and Propranolol Drug Metab. Dispos., December 1, 1997; 25(12): 1359 - 1369. [Abstract] [Full Text]
|
|
|
|
|
|
M. Kitani, G. Miyamoto, M. Nagasawa, T. Yamada, J. Matsubara, M. Uchida, and M. Odomi Biotransformation of the Novel Inotropic Agent Toborinone (OPC-18790) in Rats and Dogs. Evidence for the Formation of Novel Glutathione and Two Cysteine Conjugates Drug Metab. Dispos., June 1, 1997; 25(6): 663 - 674. [Abstract] [Full Text]
|
|
|
|
 |
|
 Y.W. F. Lam and M. V. Marshall Genetically Determined Polymorphisms in Drug Metabolism Journal of Pharmacy Practice, January 1, 1992; 5(6): 317 - 336. [Abstract] [PDF]
|
|
|
|
|
|
R. J. Straka and P. S. Marshall The Clinical Significance of the Pharmacogenetics of Cardiovascular Medications Journal of Pharmacy Practice, January 1, 1992; 5(6): 337 - 361. [Abstract] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
